CLARUS THERAPEUTICS HOLDINGS (CRXT) Stock Fundamental Analysis

NASDAQ:CRXT • US18271L1070

0.099 USD
-0.06 (-36.94%)
At close: Aug 30, 2022
0.101 USD
+0 (+2.02%)
After Hours: 8/30/2022, 8:05:42 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, CRXT scores 2 out of 10 in our fundamental rating. CRXT was compared to 193 industry peers in the Pharmaceuticals industry. The financial health of CRXT is average, but there are quite some concerns on its profitability. CRXT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • CRXT had negative earnings in the past year.
CRXT Yearly Net Income VS EBIT VS OCF VS FCFCRXT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 0 -10M -20M -30M -40M

1.2 Ratios

Industry RankSector Rank
ROA -66.68%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRXT Yearly ROA, ROE, ROICCRXT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 0 200 -200 -400

1.3 Margins

Industry RankSector Rank
OM -235.99%
PM (TTM) -193%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRXT Yearly Profit, Operating, Gross MarginsCRXT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • CRXT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CRXT remains at a similar level compared to 1 year ago.
  • The debt/assets ratio for CRXT has been reduced compared to a year ago.
CRXT Yearly Shares OutstandingCRXT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 5M 10M 15M 20M
CRXT Yearly Total Debt VS Total AssetsCRXT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -11.36, we must say that CRXT is in the distress zone and has some risk of bankruptcy.
  • There is no outstanding debt for CRXT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.36
ROIC/WACCN/A
WACC6.15%
CRXT Yearly LT Debt VS Equity VS FCFCRXT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 0 50M -50M -100M

2.3 Liquidity

  • CRXT has a Current Ratio of 0.79. This is a bad value and indicates that CRXT is not financially healthy enough and could expect problems in meeting its short term obligations.
  • A Quick Ratio of 0.52 indicates that CRXT may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.52
CRXT Yearly Current Assets VS Current LiabilitesCRXT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 43.66% over the past year.
  • CRXT shows a strong growth in Revenue. In the last year, the Revenue has grown by 39.87%.
EPS 1Y (TTM)43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.34%
Revenue 1Y (TTM)39.87%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-20.73%

3.2 Future

  • CRXT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.39% yearly.
  • CRXT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 57.00% yearly.
EPS Next Y87.39%
EPS Next 2Y39.54%
EPS Next 3Y25.66%
EPS Next 5Y14.39%
Revenue Next Year35.11%
Revenue Next 2Y52.3%
Revenue Next 3Y53.57%
Revenue Next 5Y57%

3.3 Evolution

CRXT Yearly Revenue VS EstimatesCRXT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
CRXT Yearly EPS VS EstimatesCRXT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CRXT. In the last year negative earnings were reported.
  • Also next year CRXT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRXT Price Earnings VS Forward Price EarningsCRXT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRXT Per share dataCRXT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CRXT's earnings are expected to grow with 25.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.54%
EPS Next 3Y25.66%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CRXT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CLARUS THERAPEUTICS HOLDINGS

NASDAQ:CRXT (8/30/2022, 8:05:42 PM)

After market: 0.101 +0 (+2.02%)

0.099

-0.06 (-36.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-18
Earnings (Next)N/A
Inst Owners0.3%
Inst Owner Change-84%
Ins Owners9.87%
Ins Owner Change0%
Market Cap5.15M
Revenue(TTM)16.91M
Net Income(TTM)-32.63M
Analysts77.78
Price Target3.06 (2990.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.3
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.27
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.33
BVpS-0.25
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -66.68%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -235.99%
PM (TTM) -193%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.79
Quick Ratio 0.52
Altman-Z -11.36
F-Score3
WACC6.15%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.34%
EPS Next Y87.39%
EPS Next 2Y39.54%
EPS Next 3Y25.66%
EPS Next 5Y14.39%
Revenue 1Y (TTM)39.87%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-20.73%
Revenue Next Year35.11%
Revenue Next 2Y52.3%
Revenue Next 3Y53.57%
Revenue Next 5Y57%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

CLARUS THERAPEUTICS HOLDINGS / CRXT FAQ

What is the fundamental rating for CRXT stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRXT.


Can you provide the valuation status for CLARUS THERAPEUTICS HOLDINGS?

ChartMill assigns a valuation rating of 0 / 10 to CLARUS THERAPEUTICS HOLDINGS (CRXT). This can be considered as Overvalued.


How profitable is CLARUS THERAPEUTICS HOLDINGS (CRXT) stock?

CLARUS THERAPEUTICS HOLDINGS (CRXT) has a profitability rating of 1 / 10.


What is the expected EPS growth for CLARUS THERAPEUTICS HOLDINGS (CRXT) stock?

The Earnings per Share (EPS) of CLARUS THERAPEUTICS HOLDINGS (CRXT) is expected to grow by 87.39% in the next year.